Literature DB >> 30069583

Temporal changes in MRI appearance of the prostate after focal ablation.

Andreas M Hötker1,2, Andreas Meier3,4, Yousef Mazaheri5, Junting Zheng6, Marinela Capanu6, Joshua Chaim3, Ramon Sosa3, Jonathan Coleman7, Hedvig Hricak3, Oguz Akin3.   

Abstract

PURPOSE: The purpose of our study was to retrospectively evaluate and categorize temporal changes in MRI appearances of the prostate in patients who underwent focal therapy with MRI follow-up.
METHODS: The Institutional Review Board approved this retrospective study and waived the requirement for informed consent. Thirty-seven patients (median age 61; 48-70 years) with low-to-intermediate-risk, clinically organ-confined prostate cancer underwent focal ablation therapy from 2009 to 2014. Two radiologists reviewed post-treatment MRIs (n = 76) and categorized imaging features blinded to the time interval between the focal therapy and the follow-up MRI. Inter-reader agreement was assessed (kappa) and generalized linear regression was used to examine associations between an imaging feature being present/absent and days between ablation and MRI.
RESULTS: Inter-reader agreement on MRI features ranged from fair to substantial. Edema was found present at earlier times after ablation (median 16-25 days compared to MRIs without edema, median 252-514 days), as was rim enhancement of the ablation zone (18-22.5 days vs. 409-593 days), a hypointense rim around the ablation zone on T2-weighted images (53-57.5 days vs. 279-409 days) and the presence of an appreciable ablation cavity (48.5-60 days vs. 613-798 days, all p < 0.05). Enhancement of the ablation zone/scar (553-731 days vs. 61.5-162 days) and the formation of a T2-hypointense scar were found to be present on later MRI scans (514-553 days vs. 29-32 days, one reader).
CONCLUSIONS: The MRI appearance of the prostate after focal ablation changes substantially over time. Identification of temporal patterns in the appearance of imaging features should help reduce image interpretation variability and errors when assessing post-therapeutic scans.

Entities:  

Keywords:  Cryosurgery; Electroporation; Magnetic resonance imaging; Prostate cancer; Recurrence

Mesh:

Year:  2019        PMID: 30069583      PMCID: PMC6894419          DOI: 10.1007/s00261-018-1715-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  21 in total

Review 1.  Role of MRI in follow-up after focal therapy for prostate carcinoma.

Authors:  Pieter J De Visschere; Gert O De Meerleer; Jurgen J Fütterer; Geert M Villeirs
Journal:  AJR Am J Roentgenol       Date:  2010-06       Impact factor: 3.959

2.  Role of MRI in minimally invasive focal ablative therapy for prostate cancer.

Authors:  Andrew B Rosenkrantz; Stephen M Scionti; Savvas Mendrinos; Samir S Taneja
Journal:  AJR Am J Roentgenol       Date:  2011-07       Impact factor: 3.959

Review 3.  Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.

Authors:  B G Muller; W van den Bos; M Brausi; J J Fütterer; S Ghai; P A Pinto; I V Popeneciu; T M de Reijke; C Robertson; J J M C H de la Rosette; S Scionti; B Turkbey; H Wijkstra; O Ukimura; T J Polascik
Journal:  World J Urol       Date:  2015-01-06       Impact factor: 4.226

4.  Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer.

Authors:  Oguz Akin; Christopher C Riedl; Nicole M Ishill; Chaya S Moskowitz; Jingbo Zhang; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-04       Impact factor: 5.315

5.  Role of prostate biopsy schemes in accurate prediction of Gleason scores.

Authors:  Badar M Mian; David J Lehr; Courtenay K Moore; Hugh A G Fisher; Ronald P Kaufman; Jeffery S Ross; Timothy A Jennings; Tipu Nazeer
Journal:  Urology       Date:  2006-02       Impact factor: 2.649

6.  MR imaging of prostate after treatment with high-intensity focused ultrasound.

Authors:  Alexander P S Kirkham; Mark Emberton; Ivan M Hoh; Rowland O Illing; A Alex Freeman; Clare Allen
Journal:  Radiology       Date:  2008-01-25       Impact factor: 11.105

Review 7.  How to diagnose and treat focal therapy failure and recurrence?

Authors:  Eric Barret; Kadi-Ann Harvey-Bryan; Rafael Sanchez-Salas; Francois Rozet; Marc Galiano; Xavier Cathelineau
Journal:  Curr Opin Urol       Date:  2014-05       Impact factor: 2.309

8.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.

Authors:  Hashim U Ahmed; Ahmed El-Shater Bosaily; Louise C Brown; Rhian Gabe; Richard Kaplan; Mahesh K Parmar; Yolanda Collaco-Moraes; Katie Ward; Richard G Hindley; Alex Freeman; Alex P Kirkham; Robert Oldroyd; Chris Parker; Mark Emberton
Journal:  Lancet       Date:  2017-01-20       Impact factor: 79.321

9.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.

Authors:  Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

Review 10.  Multiparametric Magnetic Resonance Imaging of Recurrent Prostate Cancer.

Authors:  Daniel Corey Oppenheimer; Eric P Weinberg; Gary M Hollenberg; Steven P Meyers
Journal:  J Clin Imaging Sci       Date:  2016-04-29
View more
  2 in total

Review 1.  Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives.

Authors:  Marieke van Son; Max Peters; Marinus Moerland; Linda Kerkmeijer; Jan Lagendijk; Jochem van der Voort van Zyp
Journal:  Cancers (Basel)       Date:  2018-12-03       Impact factor: 6.639

2.  Role of multiparametric MRI in long-term surveillance following focal laser ablation of prostate cancer.

Authors:  Mark Paxton; Eitan Barbalat; Nathan Perlis; Ravi J Menezes; Mark Gertner; David Dragas; Masoom A Haider; Antonio Finelli; John Trachtenberg; Sangeet Ghai
Journal:  Br J Radiol       Date:  2021-07-29       Impact factor: 3.039

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.